Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness.

Wischmeyer PE, McDonald D, Knight R.

Curr Opin Crit Care. 2016 Aug;22(4):347-53. doi: 10.1097/MCC.0000000000000321.

PMID:
27327243
2.

Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection.

Broecker F, Klumpp J, Moelling K.

Ann N Y Acad Sci. 2016 May;1372(1):29-41. doi: 10.1111/nyas.13100. Epub 2016 Jun 10.

PMID:
27286042
3.

The Gut Microbiome and Obesity.

John GK, Mullin GE.

Curr Oncol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11912-016-0528-7. Review.

PMID:
27255389
4.

How to Manipulate the Microbiota: Fecal Microbiota Transplantation.

Fuentes S, de Vos WM.

Adv Exp Med Biol. 2016;902:143-53. doi: 10.1007/978-3-319-31248-4_10.

PMID:
27161356
5.

Fecal transplantation: any real hope for inflammatory bowel disease?

Moayyedi P.

Curr Opin Gastroenterol. 2016 Jul;32(4):282-6. doi: 10.1097/MOG.0000000000000285.

PMID:
27152872
6.

Fecal transplantation indications in ulcerative colitis. Preliminary study.

Laszlo M, Ciobanu L, Andreica V, Pascu O.

Clujul Med. 2016;89(2):224-8. doi: 10.15386/cjmed-613. Epub 2016 Apr 15.

7.

Environmental management in the gut: fecal transplantation to restore the intestinal ecosystem.

Young VB, Hayden MK.

Infect Dis (Lond). 2016 Aug;48(8):593-5. doi: 10.1080/23744235.2016.1177200. Epub 2016 May 4. No abstract available.

PMID:
27143316
8.

Checkpoint inhibitors and gastrointestinal immune-related adverse events.

Pernot S, Ramtohul T, Taieb J.

Curr Opin Oncol. 2016 Jul;28(4):264-8. doi: 10.1097/CCO.0000000000000292.

PMID:
27138569
9.

Fecal Transplantation using a Nasoenteric Tube during an Initial Episode of Severe Clostridium difficile Infection.

Jeon YD, Hong N, Kim JH, Park SH, Kim SB, Song IJ, Ann HW, Ahn JY, Kim SB, Ku NS, Lee K, Yong D, Kim JM, Choi JY.

Infect Chemother. 2016 Mar;48(1):31-5. doi: 10.3947/ic.2016.48.1.31. Epub 2016 Mar 31.

10.

Clostridium difficile infection: a review of current and emerging therapies.

Ofosu A.

Ann Gastroenterol. 2016 Apr-Jun;29(2):147-54. doi: 10.20524/aog.2016.0006. Review.

11.

The Intestinal Microbiota in Metabolic Disease.

Woting A, Blaut M.

Nutrients. 2016 Apr 6;8(4). pii: E202. doi: 10.3390/nu8040202. Review.

12.

Cytotoxicity of Nanoparticles Contained in Food on Intestinal Cells and the Gut Microbiota.

Fröhlich EE, Fröhlich E.

Int J Mol Sci. 2016 Apr 6;17(4). pii: E509. doi: 10.3390/ijms17040509. Review.

13.

Dysbiosis in intestinal inflammation: Cause or consequence.

Buttó LF, Haller D.

Int J Med Microbiol. 2016 Mar 4. pii: S1438-4221(16)30015-7. doi: 10.1016/j.ijmm.2016.02.010. [Epub ahead of print]

PMID:
27012594
14.
15.

Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, Hota S.

PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.

16.

Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Distrutti E, Monaldi L, Ricci P, Fiorucci S.

World J Gastroenterol. 2016 Feb 21;22(7):2219-41. doi: 10.3748/wjg.v22.i7.2219. Review.

17.

Peripheral Neuropathy After Fecal Microbiota Transplantation for Clostridium difficile Infection: A Case Report.

Didesch MM, Averill A, Oh-Park M.

PM R. 2016 Jan 27. pii: S1934-1482(16)00042-3. doi: 10.1016/j.pmrj.2016.01.009. [Epub ahead of print]

PMID:
26826616
18.

Fecal Transplantation for Clostridium Difficile-"All Stool May Not Be Created Equal".

Gathe JC Jr, Diejomaoh EM, Mayberry CC, Clemmons JB.

J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):107-8. doi: 10.1177/2325957415627695. Epub 2016 Jan 28.

PMID:
26821578
19.

Antibiotic-treated versus germ-free rodents for microbiota transplantation studies.

Lundberg R, Toft MF, August B, Hansen AK, Hansen CH.

Gut Microbes. 2016;7(1):68-74. doi: 10.1080/19490976.2015.1127463.

20.

[Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].

Halmos T, Suba I.

Orv Hetil. 2016 Jan 3;157(1):13-22. doi: 10.1556/650.2015.30296. Review. Hungarian.

PMID:
26708682
Items per page

Supplemental Content

Loading ...
Write to the Help Desk